ALLIANCE FOR HUMAN RESEARCH PROTECTION
Advancing Honest and Ethical Medical Research
www.ahrp.org
FYI
OBAMACARE includes a major initiative which needs close public scrutiny otherwise unsuspecting patients--in particular, patients whose medical bills are paid for by Medicare and Medicaid--will become human guinea pigs in medical experiments without their knowledge or consent.
A PhRMA-Merck sponsored Roundtable on "Comparative Effectiveness Research" is being held at the National Press Club in Washington, DC on October 29th.
The participants represent the federal government--officials from the so-called, Patient Centered Outcomes Research Institute (PCORI), the Executive Vice President & Chief Medical Officer of Merck, the President & Chief Executive Officer of PhRMA, and Academy Health--representing the major medical research centers such as Harvard, the Association of American Medical Colleges.
No one involved in formulating plans for "comparative effectiveness research" and no one at this Roundtable represents the interest of ordinary citizens who will be sought as human subjects of potentially dangerous experiments.
The prototype for such "comparative effectiveness research" is the controversial, unethical oxygen-restricted SUPPORT experiment that was conducted on 1,316 extremely vulnerable, premature babies. A two-year investigation by the federal oversight agency (OHRP) determined that SUPPORT was conducted in violation of federal informed consent requirements.
In fact, parents were deceived--just as as parents had been deceived about the unethical radiation experiments conducted on their children in the 1950s, 1960s and 1970s before there were federal regulations requiring full disclosure of the foreseeable risks.
Neither parents were informed about the nature of the experiment and the risks involved for their babies. The babies were randomized--without regard for their physical condition or oxygen need--to receive either high or low oxygen supplements. The deceptive consent documents stated: "because all the treatments proposed...are standard of care, there is no predictable increase risk for the babies." But in fact, NONE of the babies in SUPPORT received standard of care.
The SUPPORT death toll:
130 babies who were randomized to the restricted low oxygen group died (20%); and 107 babies randomized to the high oxygen group died (16%).
SUPPORT researchers complained that it takes "too much effort" to obtain consent; some mothers were approached up to 11 times to give their consent, yet, 47% refused. The researchers urged that informed consent be waived for similar trials.
The promoters of "comparative effectiveness research" would have you believe that there are no risks from "CER" research--they seek waivers from federal informed consent and disclosure requirements. They would revert medical research to the pre-Nuremberg Code "good old days."
See detailed, documented evidence--from HHS sources--that back up our claim:
http://www.regulations.gov/#!documentDetail;D=HHS-OPHS-2013-0004-0033
(it takes several clicks on the government website)
(AHRP will re-post several submissions to HHS Docket 2013-0004)
Vera Sharav
http://www.nehi.net/events/92/expert_roundtable_comparative_effectiveness_research_where_are_we_and_where_are_we_going
NEW ENGLAND HEALTH INSTITUTE
PRESS RELEASE: Comparative Effectiveness Research: Where Are We and Where Are We Going?
l2:30 PM: Registration
1:00 - 4:30 PM: Roundtable Discussion
MERCK PhRMA
Advancing Honest and Ethical Medical Research
www.ahrp.org
FYI
OBAMACARE includes a major initiative which needs close public scrutiny otherwise unsuspecting patients--in particular, patients whose medical bills are paid for by Medicare and Medicaid--will become human guinea pigs in medical experiments without their knowledge or consent.
A PhRMA-Merck sponsored Roundtable on "Comparative Effectiveness Research" is being held at the National Press Club in Washington, DC on October 29th.
The participants represent the federal government--officials from the so-called, Patient Centered Outcomes Research Institute (PCORI), the Executive Vice President & Chief Medical Officer of Merck, the President & Chief Executive Officer of PhRMA, and Academy Health--representing the major medical research centers such as Harvard, the Association of American Medical Colleges.
No one involved in formulating plans for "comparative effectiveness research" and no one at this Roundtable represents the interest of ordinary citizens who will be sought as human subjects of potentially dangerous experiments.
The prototype for such "comparative effectiveness research" is the controversial, unethical oxygen-restricted SUPPORT experiment that was conducted on 1,316 extremely vulnerable, premature babies. A two-year investigation by the federal oversight agency (OHRP) determined that SUPPORT was conducted in violation of federal informed consent requirements.
In fact, parents were deceived--just as as parents had been deceived about the unethical radiation experiments conducted on their children in the 1950s, 1960s and 1970s before there were federal regulations requiring full disclosure of the foreseeable risks.
Neither parents were informed about the nature of the experiment and the risks involved for their babies. The babies were randomized--without regard for their physical condition or oxygen need--to receive either high or low oxygen supplements. The deceptive consent documents stated: "because all the treatments proposed...are standard of care, there is no predictable increase risk for the babies." But in fact, NONE of the babies in SUPPORT received standard of care.
The SUPPORT death toll:
130 babies who were randomized to the restricted low oxygen group died (20%); and 107 babies randomized to the high oxygen group died (16%).
SUPPORT researchers complained that it takes "too much effort" to obtain consent; some mothers were approached up to 11 times to give their consent, yet, 47% refused. The researchers urged that informed consent be waived for similar trials.
The promoters of "comparative effectiveness research" would have you believe that there are no risks from "CER" research--they seek waivers from federal informed consent and disclosure requirements. They would revert medical research to the pre-Nuremberg Code "good old days."
See detailed, documented evidence--from HHS sources--that back up our claim:
http://www.regulations.gov/#!documentDetail;D=HHS-OPHS-2013-0004-0033
(it takes several clicks on the government website)
(AHRP will re-post several submissions to HHS Docket 2013-0004)
Vera Sharav
http://www.nehi.net/events/92/expert_roundtable_comparative_effectiveness_research_where_are_we_and_where_are_we_going
NEW ENGLAND HEALTH INSTITUTE
PRESS RELEASE: Comparative Effectiveness Research: Where Are We and Where Are We Going?
An expert roundtable on the impact of
expanded
comparative effectiveness research on innovation.
October 29, 2013 12:30 -
4:30 PM l2:30 PM: Registration
1:00 - 4:30 PM: Roundtable Discussion
WASHINGTON DC, USA -- HEALTHCARE UPDATE NEWS
SERVICE™ --
SEPTEMBER 27, 2013: Join NEHI and the California Healthcare
Institute for a
half-day conference focusing on the current state of CER and
innovation.
Experts will assess how the landscape has evolved and discuss
emerging trends
such as Big Data, HIT, personalized medicine, and their impact on
the future of
CER.
LOCATION The National Press Club,
Holeman Lounge
529 l4th St NW Washington, DC
529 l4th St NW Washington, DC
Featured Participants:
Cliff Goodman, PhD Senior Vice
President and Director, Center for Comparative Effectiveness
Research, Lewin Group, Moderator
Anne Beal, MD Deputy Executive
Director & Chief Officer for Engagement, PCORI
John Castellani President & Chief Executive Officer, PhRMA
John Castellani President & Chief Executive Officer, PhRMA
Erin Holve, PhD Senior Director,
Academy Health
Eric Perakslis, PhD Executive
Director, Center for Biomedical Informatics & the Countway
Library of Medicine, Harvard Medical School
Alan Rosenberg, MD Vice President of
Clinical Pharmacy & Medical Policy Programs, WellPoint, Inc.;
Advisory Panel, PCORI
Michael Rosenblatt, MD Executive Vice
President & Chief Medical Officer, Merck
Jean Slutsky Director, Center for
Outcomes and Evidence, AHRQ
MANY THANKS TO OUR EVENT
SPONSORS!
MERCK PhRMA
"C
For kids, health problems can lead to academic problems, and good
health has been positively linked to good grades. The Affordable Care
Act, passed in 2010, will support the health of America's children and
youth through three major school-based strategies: school-based health
centers, school-community health partnerships, and support for expectant
and parenting teens. Learn what this means for schools, parents, and
their children in our latest blog post.
If you run a nonprofit organization, this is the conference for you. "After
the Leap" is a two-day conference that will help executives learn more
about outcomes measurement, performance management, and organizational
change, hosted by 
"T
